A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content
- 1 July 1997
- journal article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 30 (1) , 105-112
- https://doi.org/10.1016/s0272-6386(97)90571-0
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Relative effects of PTH and dietary phosphorus on calcitriol production in normal and azotemic ratsKidney International, 1996
- Metabolism of 1,25(OH)216-ene D3 in kidney: influence of structural modification of d-ring on side chain metabolismBioorganic & Medicinal Chemistry Letters, 1993
- Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patientsKidney International, 1992
- 22-oxacalcitriol suppresses 25-hydroxycholecalciferol-1α-hydroxylase in rat kidneyBiochemical and Biophysical Research Communications, 1992
- Regulation of parathyroid hormone synthesis in chronic renal failure in ratsKidney International, 1991
- Attenuated Rise of 1,25 (OH)2 Vitamin D3 in Response to Parathyroid Hormone in Patients with Incipient Renal FailureNephron, 1991
- Intravenous Calcitriol in the Treatment of Refractory Osteitis Fibrosa of Chronic Renal FailureNew England Journal of Medicine, 1989
- Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium.Journal of Clinical Investigation, 1989
- Calcium Carbonate as a Phosphate Binder in Patients with Chronic Renal Failure Undergoing DialysisNew England Journal of Medicine, 1986
- Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.Journal of Clinical Investigation, 1984